Biomarker-based staging of Alzheimer disease: rationale and clinical applications

J Therriault, SE Schindler, G Salvadó… - Nature Reviews …, 2024 - nature.com
Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Blood biomarkers to detect Alzheimer disease in primary care and secondary care

S Palmqvist, P Tideman, N Mattsson-Carlgren… - JAMA, 2024 - jamanetwork.com
Importance An accurate blood test for Alzheimer disease (AD) could streamline the
diagnostic workup and treatment of AD. Objective To prospectively evaluate a clinically …

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer's disease

KA Josephs, N Tosakulwong, SD Weigand… - Science translational …, 2024 - science.org
[18F]-Flortaucipir positron emission tomography (PET) is considered a good biomarker of
Alzheimer's disease. However, it is unknown how flortaucipir is associated with the …

Olfactory deficit: a potential functional marker across the Alzheimer's disease continuum

D Liu, J Lu, L Wei, M Yao, H Yang, P Lv… - Frontiers in …, 2024 - frontiersin.org
Alzheimer's disease (AD) is a prevalent form of dementia that affects an estimated 32 million
individuals globally. Identifying early indicators is vital for screening at-risk populations and …

[PDF][PDF] A data-driven study of Alzheimer's disease related amyloid and tau pathology progression

LM Aksman, NP Oxtoby, MA Scelsi, PA Wijeratne… - Brain, 2023 - academic.oup.com
Amyloid-β is thought to facilitate the spread of tau throughout the neocortex in Alzheimer's
disease, though how this occurs is not well understood. This is because of the spatial …

Association of quantitative histopathology measurements with antemortem medial temporal lobe cortical thickness in the Alzheimer's disease continuum

AE Denning, R Ittyerah, LM Levorse… - Acta …, 2024 - Springer
The medial temporal lobe (MTL) is a hotspot for neuropathology, and measurements of MTL
atrophy are often used as a biomarker for cognitive decline associated with …

Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease

SN Roemer-Cassiano, F Wagner… - Science Translational …, 2025 - science.org
In Alzheimer's disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau
pathology, which drives neurodegeneration and cognitive decline. However, the …

Review on anti-alzheimer drug development: approaches, challenges and perspectives

AE Abdallah - RSC advances, 2024 - pubs.rsc.org
Alzheimer is an irreversible progressive neurodegenerative disease that causes failure of
cerebral neurons and disability of the affected person to practice normal daily life activities …

Towards in vivo PET imaging of primary age-related tauopathy

J Therriault, MJ Grothe - Brain, 2023 - academic.oup.com
Towards in vivo PET imaging of primary age-related tauopathy | Brain | Oxford Academic Skip to
Main Content Advertisement Oxford Academic Journals Books Search Menu Information …

[18F] 2-fluoro-2-deoxy-sorbitol ([18F] FDS) PET imaging repurposed for quantitative estimation of blood-brain barrier permeability in a rat model of Alzheimer's disease

A Soyer, S Goutal, S Leterrier, S Marie, B Larrat… - Annales …, 2024 - Elsevier
Numerous studies suggest that blood-brain barrier (BBB) dysfunction may contribute to the
progression of Alzheimer's disease (AD). Clinically available neuroimaging methods are …